We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Globus Medical (GMED) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts forecast that Globus Medical (GMED - Free Report) will report quarterly earnings of $0.92 per share in its upcoming release, pointing to a year-over-year increase of 35.3%. It is anticipated that revenues will amount to $730.32 million, exhibiting an increase of 22.1% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Globus Medical metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Sales by Product Category- Enabling Technologies' of $27.65 million. The estimate points to a change of +24.6% from the year-ago quarter.
Analysts expect 'Net Sales by Product Category- Musculoskeletal Solutions' to come in at $698.01 million. The estimate indicates a change of +21.2% from the prior-year quarter.
Analysts predict that the 'Geographic Revenues- International' will reach $138.33 million. The estimate indicates a change of +21.1% from the prior-year quarter.
The average prediction of analysts places 'Geographic Revenues- United States' at $587.33 million. The estimate indicates a change of +21.4% from the prior-year quarter.
Globus Medical shares have remained unchanged in the past month, in contrast to the Zacks S&P 500 composite's +10.3% move. With a Zacks Rank #1 (Strong Buy), GMED is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Globus Medical (GMED) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts forecast that Globus Medical (GMED - Free Report) will report quarterly earnings of $0.92 per share in its upcoming release, pointing to a year-over-year increase of 35.3%. It is anticipated that revenues will amount to $730.32 million, exhibiting an increase of 22.1% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Globus Medical metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Sales by Product Category- Enabling Technologies' of $27.65 million. The estimate points to a change of +24.6% from the year-ago quarter.
Analysts expect 'Net Sales by Product Category- Musculoskeletal Solutions' to come in at $698.01 million. The estimate indicates a change of +21.2% from the prior-year quarter.
Analysts predict that the 'Geographic Revenues- International' will reach $138.33 million. The estimate indicates a change of +21.1% from the prior-year quarter.
The average prediction of analysts places 'Geographic Revenues- United States' at $587.33 million. The estimate indicates a change of +21.4% from the prior-year quarter.
View all Key Company Metrics for Globus Medical here>>>Globus Medical shares have remained unchanged in the past month, in contrast to the Zacks S&P 500 composite's +10.3% move. With a Zacks Rank #1 (Strong Buy), GMED is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .